Pneumococcal Conjugate Vaccine Adjuvanting for Broader Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pneumococcal vaccines are limited in their ability to protect against a wide range of pneumococcal serotypes, including emerging strains, and require higher antibody titers for effective opsonophagocytic killing responses.
Innovation Solution
The development of pneumococcal conjugate vaccines adjuvanted with a saponin-based adjuvant, such as Matrix-M, which enhances the immunogenic response by increasing antigen density and improving both innate and adaptive immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional pneumococcal vaccines are used, then protection against specific serotypes is achieved, but the ability to protect against emerging strains and non-vaccine serotypes is limited
Solution Approach 1:
The patent changes the immunological parameters of the vaccine by incorporating saponin-based adjuvants (Matrix-M) that modify the immune response characteristics. This allows the vaccine to generate broader antibody responses against multiple serotypes including emerging strains, while maintaining effectiveness against vaccine-covered serotypes through enhanced immunogenicity
2Reliability
If higher antibody titers are required for effective opsonophagocytic killing, then protection efficacy is improved, but vaccine immunogenicity must be significantly enhanced
Solution Approach 1:
The saponin-based adjuvant Matrix-M acts as an intermediary substance that bridges the antigen and the immune system. It enhances the presentation and processing of pneumococcal antigens, leading to stronger and more sustained antibody responses that achieve the required opsonophagocytic killing titers more effectively
Solution Approach 2:
The vaccine formulation uses a composite adjuvant system combining saponin-based Matrix-M with traditional aluminum adjuvant. This composite approach synergistically enhances immunogenicity, producing both humoral and cellular immune responses that collectively achieve higher antibody titers for effective opsonophagocytic killing
3Productivity
If vaccine formulations are optimized for maximum immunogenicity, then immune response is enhanced, but manufacturing complexity and stability requirements increase
Solution Approach 1:
The patent applies local quality enhancement by incorporating saponin-based adjuvant specifically in the formulation to target and enhance the immune response at the site of injection. This localized enhancement achieves superior immunogenicity without requiring complex changes to the entire vaccine manufacturing process or storage infrastructure
Data Source
AI summary
The invention is directed to an immunogenic composition comprising one or more conjugated bacterial capsular polysaccharides derived from Streptococcus pneumoniae serotypes, a saponin-based adjuvant, and a pharmaceutically acceptable carrier. The invention includes a method of preventing, treating or ameliorating a Streptococcus pneumoniae infection, disease or condition in a subject, comprising administering to the subject an effective amount of an immunogenic composition comprising one or more conjugated bacterial capsular polysaccharides derived from Streptococcus pneumoniae serotypes, a saponin-based adjuvant, and a pharmaceutically acceptable carrier.